Since the discovery of activating EGFR mutation, TKIs are currently the standard of care for advanced NSCLC patients which provide strong anti-tumor activity compared to platinum-based chemotherapy (Hanna et al., 2017; Yoneda et al., 2019). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.